Elexacaftor, ivacaftor, and tezacaftor

(Trikafta®)

Elexacaftor, ivacaftor, and tezacaftor

Drug updated on 11/14/2023

Dosage FormTablet (oral:100 mg elexacaftor, 50 mg tezacaftor, and 75 mg ivacaftor, co-packaged with 150 mg ivacaftor)
Drug ClassCFTR Potentiators
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.

Product Monograph / Prescribing Information

Document TitleYearSource
Trikafta (elexacaftor, ivacaftor, and tezacaftor) Prescribing Information.2021Vertex Pharmaceuticals Inc., Boston, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines